# A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer

> **NCT03808870** · PHASE1 · COMPLETED · sponsor: **NatureWise Biotech & Medicals Corporation** · enrollment: 21 (actual)

## Conditions studied

- Malignant Neoplasm

## Interventions

- **DRUG:** NBM-BMX softgel capsules

## Key facts

- **NCT ID:** NCT03808870
- **Lead sponsor:** NatureWise Biotech & Medicals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-28
- **Primary completion:** 2022-02-12
- **Final completion:** 2022-02-16
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2023-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03808870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03808870, "A Safety and Pharmacokinetic Study of NBM-BMX Administered Orally to Asian Patients With Advanced Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03808870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*